

## Press Release

**DIASORIN SIGNS A 5-YEAR COOPERATION AGREEMENT WITH ROCHE TO CONNECT ITS LIAISON XL SYSTEM TO THE COBAS 8100 AUTOMATED WORKFLOW SERIES FROM ROCHE**

October 29, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce that it has signed a **5-year agreement** with **Roche** (SIX: RO, ROG; OTCQX: RHHBY) to allow the connectivity of the **LIAISON XL** System to the **cobas 8100® automated workflow series** in the High Volume Laboratories requesting to fully automate their diagnostic processes.

The agreement also **allows Roche to exclusively represent part of the DiaSorin's specialty assays in this market segment**, in association with the Cobas 8100 platform.

Consolidation of laboratories around the world is a process that has been accelerating in the past few years driven by the necessity to achieve better productivity and savings in the management of the increased demands for diagnostic testing.

As a consequence, the **number of high volume laboratories** in need for Total Laboratory Automation is **expected** to constantly grow and exceed **1,000 labs within the next 5 years**.

This market evolution sets a **solid opportunity that DiaSorin intends to exploit** working together with the IVD industry leader by connecting the state of the art **cobas 8100 automated workflow series** and the **DiaSorin Liaison XL system with its unique panel of specialties**.

The connectivity of the two systems is meant to **address the rising demand of a broader and complete solution by high volume laboratories**, requiring analytical set-up flexibility and a broader online menu of both routine and specialty assays.

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: ***"This agreement with Roche represents for us a milestone which enables our Group to address a growing market opportunity with our LIAISON XL products and systems.***

*Our specialty portfolio of products fits well with the high volume Lab Automation System of Roche in a market segment where the combination of high volume routine assays and specialized assays will finally allow customers to address in a more complete manner their increasing need of full automation".*

**About DiaSorin**

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. For more information, please visit [www.diasorin.com](http://www.diasorin.com).

**About Roche**

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com).

**For additional information, please contact:****For DiaSorin Group**

Riccardo Fava

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

[margherita.sacerdoti@diasorin.it](mailto:margherita.sacerdoti@diasorin.it)